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 Currently, regenerative medicine is seen as a promising alternative to traditional therapies. 14 
Tapping into the natural ability of the body to self-restore and heal opens up great potential to treat 15 
many disorders, including those which were considered untreatable or for which current approaches 16 
do not result in adequate or timely recovery. Stem cells are often considered a "magic bullet" to boost 17 
natural regenerative potential. Indeed, these cells are capable of self renewal, thus forming a 18 
practically unlimited pool of "spare parts", turning into almost any type of adult somatic cells, 19 
replacing dying aged cells or healing injuries. Isolated and (if necessary) expanded in vitro or ex vivo 20 
these cells find more therapeutic applications. Importantly, recent advances in biomedicine suggests 21 
that the main therapeutic effects of such stem cell transplantation is not dependent on cell 22 
replacement, but rather on paracrine stimulation of regenerative potential of resident cells through 23 
cell to cell signaling, consisting of direct contact, soluble protein factors, metabolites and 24 
microvesicles. So instead of using stem cell transplantation scientists and clinicians are considering 25 
other biologically active substances, which don't contain live cells but contain, for example, growth 26 
factors which these cells would secrete. One such approach which has already found wide spread 27 
clinical applications is platelet rich plasma, which contains high concentrations of growth factors, 28 
other cytokines or even purified recombinant protein growth factors. However, the main disadvantage 29 
of such cell-free approaches is the short half-life of transferred biologically active substances, which 30 
are rapidly degraded by body. 31 
Gene therapy is a new rapidly evolving therapeutic tool which has the potential to provide 32 
continuous stimulation of regeneration. Basically, we are ‘hacking’ host cell genomes by transferring 33 
small sections of new genetic programs in the forms of recombinant DNA or RNA molecules. These 34 
nucleic acids (in the forms of either pure (naked) plasmid DNA, nano-sized complexes or viral particles) 35 
encode different recombinant genes which are then transcribed and translated by host machinery, 36 
resulting in the biosynthesis of therapeutic proteins. Thus, instead of repeated delivery of therapeutic 37 
drugs (pharmaceuticals, recombinant proteins, etc.) we teach the organism how to continuously make 38 
its own medicine. A brilliantly technological yet natural healing mechanism.  39 
Presently most of the attention in regenerative medicine is paid towards treating human 40 
diseases. Animals, for the most part, are considered only as models for testing human drugs. Although 41 
we do see therapeutic efficiency of such treatments in many animal models, there are often 42 
differences in the composition of biopharmaceuticals because of genetic differences between humans 43 
and animals. These differences have the potential to limit efficiency of human drugs for treating 44 
animal diseases due to incomplete homology. Even more importantly, such drugs could raise 45 
immunogenicity issues, potentially having long term immunological problems, development of 46 
autoimmunity and decreased efficiency of subsequent treatments, or even negative side-effects 47 
including anaphylactic shock. When it comes to autologous (or even allogeneic) transplantation or 48 
corresponding animal cell-free products, such as platelet-rich plasma, it is not a problem. But in cases 49 
of more advanced therapeutic approaches, such as gene therapy, complete homology might be vital. 50 
This is why we are focusing our research on developing gene therapy applications using 51 
species specific recombinant genes, which will provide full biological activity and simultaneously have 52 
no immunological side effects. We have developed plasmid DNA gene therapy drugs, encoding horse 53 
specific genes. For example, plasmid DNA encoding equine vascular endothelial growth factor (VEGF) 54 
and fibroblast growth factor 2 (FGF2) [1] which demonstrated safety and efficiency in a recently 55 
published case report study of treating tendinitis and desmitis in horses [2]. Treatment of these 56 
conditions is a tedious task for veterinary doctors. Existing techniques using autologous or allogeneic 57 
stem cells or platelet-rich plasma injections have limited efficiency, thus making development of new 58 
strategies for tendon regeneration of great importance. The mechanisms of action of the gene therapy 59 
involving VEGF and FGF2 probably involves increased vascularization of damaged tissues, resulting in 60 
higher rate of regeneration. Both VEGF and FGF2 are well known growth factors with wide spectrum 61 
of mitogenic and angiogenic activity. They also promote regeneration of muscular and connective 62 
tissue. More importantly, in combination these growth factors demonstrate synergetic effects, which 63 
surpass effect of single growth factor therapy applications.  64 
With gene therapy becoming such a viable option, much consideration needs to be given to 65 
not only the design and development of new therapies and applications, but also to how animals 66 
receive treatment. The need for training for both established veterinary surgeons and undergraduate 67 
students is becoming essential. Initially the regimes will be implemented by veterinary gene therapy 68 
specialists but over time these therapies will be used in clinics throughout the world. Naturally much 69 
care and consideration is also required in ensuring that all new therapies are appropriately tested and 70 
have high standards of production and regulation. In addition these treatments will need to be 71 
discussed with the international associations involved in the regulation and breeding of horses. As 72 
with any new treatment the matter of educating and informing the public, owners, health and welfare 73 
providers and veterinary professionals is of utmost importance. With so many types of gene delivery 74 
potentially available and so many more being developed and trialed, the intricacies of each treatment 75 
for differing conditions can be difficult to portray to the owner. As of December 2017, three human 76 
gene therapy drugs had been approved by the United States Food and Drug Administration [3]. With 77 
our latest successful trials and the advances in technology and genetics, the future for veterinary gene 78 
therapy looks promising and it is likely that many more therapies will become licensed for use in both 79 
human and animal medicine.      80 
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